Shares of Ligand (NASDAQ: LGND) popped 13% today after its partner GlaxoSmithKline's (NYSE: GSK) drug Promacta received an additional indication (an FDA approval) to increase low blood platelet levels in cases of chronic hepatitis C. However, new advances in hepatitis C care are revolutionizing treatment ideas that may take the wind out of Ligand's sails.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.